One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC.
Stinchcombe, Thomas E. MD 1,2,,
doi : 10.1200/JCO.22.02790
Volume 41(13) pgs. 2303-2454 May 1, 2023
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer .
Johnson, David H.; Fehrenbacher, Louis; Novotny, William F.; Herbst, Roy S.; Nemunaitis, John J.; Jablons, David M.; Langer, Corey J.; DeVore, Russell F. III; Gaudreault, Jacques; Damico, Lisa A.; Holmgren, Eric; Kabbinavar, Fairooz
doi : 10.1200/JCO.22.02543
To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer.
Good Radiosensitizer Hunting.
Mell, Loren K. MD 1,,; Wong, Stuart J. MD 2,
doi : 10.1200/JCO.22.02350
Causal Inference in Oncology Comparative Effectiveness Research Using Observational Data: Are Instrumental Variables Underutilized?.
Perraillon, Marcelo Coca PhD 1; Tina Shih, Ya-Chen PhD 2,,
doi : 10.1200/JCO.22.02853
When Can We Retire 3,600 cGy Craniospinal Irradiation in Medulloblastoma?.
Fisher, Paul Graham MD 1,,
doi : 10.1200/JCO.23.00008
Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same.
Deek, Matthew P. MD 1,; Haigentz, Missak MD 2,; Jabbour, Salma K. MD 1,
doi : 10.1200/JCO.22.02316
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right?.
Naoum, George E. MD, MMSCI 1; Taghian, Alphonse G. MD, PhD 2,,
doi : 10.1200/JCO.22.02171
Pediatric Rhabdomyosarcoma Protocols Should Include More Detailed Imaging Guidelines to Ensure Homogeneous Response Assessment.
Schoot, Reineke A. MD, PhD 1,,; Shulkin, Barry L. MD, MBA 2,; van Rijn, Rick R. MD, PhD 3,; von Kalle, Thekla MD, PD 4
doi : 10.1200/JCO.22.02613
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study.
Bisogno, Gianni MD, PhD 1,2,,; Minard-Colin, Veronique MD, PhD 3,; Zanetti, Ilaria BSc 2; Ferrari, Andrea MD 4; Gallego, Soledad MD, PhD 5,; Davila Fajardo, Raquel MD, PhD 6,7; Mandeville, Henry MD 8,; Kelsey, Anna MD 9,; Alaggio, Rita MD 10; Orbach, Daniel MD, PhD 11,; Terwisscha van Scheltinga, Sheila MD 7; Guillen Burrieza, Gabriela MD 12; Ben-Arush, Myriam MD 13; Glosli, Heidi MD 14; Mudry, Peter MD 15; Ferman, Sima MD 16; Devalck, Christine MD 17; Defachelles, Anne Sophie MD 18; Merks, Johannes Hendrikus Maria MD, PhD 7,19,; Jenney, Meriel MD, PhD 20,
doi : 10.1200/JCO.22.02093
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.
Patil, Vijay Maruti MBBS, MD, DM 1,; Noronha, Vanita MBBS, MD, DM 1,; Menon, Nandini MBBS, MD, DNB 1; Singh, Ajay MBBS, MD, DM 1; Ghosh-Laskar, Sarbani MBBS, MD 2; Budrukkar, Ashwini MBBS, MD 2; Bhattacharjee, Atanu PhD 3; Swain, Monali MBBS, MD 2; Mathrudev, Vijayalakshmi BHMS, MBA 1; Nawale, Kavita PGDCR 1; Balaji, Arun MASLP 4; Peelay, Zoya MSc 1; Alone, Mitali MSc 1; Pathak, Shruti MSc 1; Mahajan, Abhishek MBBS, MD 5; Kumar, Suman MBBS, DNB 5; Purandare, Nilendu MBBS, DNB 6; Agarwal, Archi MBBS, DNB 6; Puranik, Ameya MBBS, DNB 6; Pendse, Shantanu MBBS, MD, DM 1; Reddy Yallala, Monica MBBS, MD 1; Sahu, Harsh MBBS, MD 1; Kapu, Venkatesh MBBS, MD 1; Dey, Sayak MBBS, MD 1; Choudhary, Jatin MBBS, MD 1; Krishna, Madala Ravi MBBS, MD 1; Shetty, Alok MBBS, MD 1; Karuvandan, Naveen MBBS, MD 1; Ravind, Rahul MBBS, MD, DM 1; Rai, Rahul MBBS, MD 1; Jobanputra, Kunal MBBS, MD 1; Chaturvedi, Pankaj MBBS, MS 7; Pai, Prathamesh S. MBBS, MS 7; Chaukar, Devendra MBBS, MS 7; Nair, Sudhir MBBS, MS 7; Thiagarajan, Shivakumar MBBS, MS 7; Prabhash, Kumar MBBS, MD, DM 1,
doi : 10.1200/JCO.22.00980
There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing chemoradiation.
Use of Instrumental Variable Analyses for Evaluating Comparative Effectiveness in Empirical Applications of Oncology: A Systematic Review.
Lu, Brandon BSc 1; Thomson, Sasha BSc 1; Blommaert, Scott BSc 1; Tadrous, Mina PharmD, MSc, PhD 2,3; Earle, Craig C. MD, MSc 1,4; Chan, Kelvin K.W. MD, PhD 1,5,6,
doi : 10.1200/JCO.22.00023
This systematic review aims to characterize the use and trends of instrumental variables (IVs) in oncology research, assess the quality and completeness of IV reporting, and evaluate the agreement and interpretation of IV results in comparison with other techniques used for determining comparative effectiveness in observational research.
The Burden of Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in Ontario, Canada.
Coltin, Hallie MD, MSc 1,2,3; Pequeno, Priscila MSc 4; Liu, Ning PhD 4,5; Tsang, Derek S. MD 6,; Gupta, Sumit MD, PhD 1,4,; Taylor, Michael D. MD, PhD 2,7; Bouffet, Eric MD 1,; Nathan, Paul C. MD, MSc 1,4; Ramaswamy, Vijay MD, PhD 1,2,8,
doi : 10.1200/JCO.22.02466
Survivors of childhood medulloblastoma suffer from substantial late effects. We characterized these sequelae using real-world health services data in a population-based cohort of medulloblastoma survivors.
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Abbou, Samuel MD 1,2; Klega, Kelly MS 1; Tsuji, Junko PhD 3; Tanhaemami, Mohammad MS 1; Hall, David MS 4; Barkauskas, Donald A. PhD 4,5,; Krailo, Mark D. PhD 4,5,; Cibulskis, Carrie BA 3; Nag, Anwesha PhD 1; Thorner, Aaron R. PhD 1; Pollock, Samuel BA 3; Imamovic-Tuco, Alma PhD 1,3; Shern, Jack F. MD 6,7; DuBois, Steven G. MD 1,; Venkatramani, Rajkumar MD 8; Hawkins, Douglas S. MD 9,; Crompton, Brian D. MD 1,3,
doi : 10.1200/JCO.22.00409
Novel biomarkers are needed to differentiate outcomes in intermediate-risk rhabdomyosarcoma (IR RMS). We sought to evaluate strategies for identifying circulating tumor DNA (ctDNA) in IR RMS and to determine whether ctDNA detection before therapy is associated with outcome.
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
Bogart, Jeffrey MD 1,,; Wang, Xiaofei MD 2; Masters, Gregory MD 3; Gao, Junheng MD 2; Komaki, Ritsuko MD 4; Gaspar, Laurie E. MD 5,6,; Heymach, John MD 4,; Bonner, James MD 7,; Kuzma, Charles MD 8; Waqar, Saiama MD 9,; Petty, William MD 10,; Stinchcombe, Thomas E. MD 11,; Bradley, Jeffrey D. MD 12,; Vokes, Everett MD 13,
doi : 10.1200/JCO.22.01359
Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily regimens in clinical practice. Whether increasing radiotherapy dose improves outcomes remains to be prospectively demonstrated.
Prospective Multicenter Diagnostic Performance of Technologist-Performed Screening Breast Ultrasound After Tomosynthesis in Women With Dense Breasts (the DBTUST).
Berg, Wendie A. MD, PhD 1,,; Zuley, Margarita L. MD 1,; Chang, Thomas S. MD 2,; Gizienski, Terri-Ann MD 1,; Chough, Denise M. MD 1; Bohm-Velez, Marcela MD 2; Sharek, Danielle E. MD 2; Straka, Michelle R. MD 2; Hakim, Christiane M. MD 1; Hartman, Jamie Y. MD 1; Harnist, Kimberly S. MD 1; Tyma, Cathy S. MD 1,3; Kelly, Amy E. MD 1; Waheed, Uzma MD 1,4,; Houshmand, Golbahar MD 1,5; Nair, Bronwyn E. MD 1; Shinde, Dilip D. MD 1; Lu, Amy H. MD 1; Bandos, Andriy I. PhD 6,; Berg, Jeremy M. PhD 7; Lettiere, Nicole B. BS 1,8,; Ganott, Marie A. MD 1
doi : 10.1200/JCO.22.01445
To assess diagnostic performance of digital breast tomosynthesis (DBT) alone or combined with technologist-performed handheld screening ultrasound (US) in women with dense breasts.
Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation.
Crivello, Pietro PhD 1; Arrieta-Bolanos, Esteban PhD 1,2; He, Meilun MPH 3; Wang, Tao PhD 4,5; Fingerson, Stephanie MS 3; Gadalla, Shahinaz M. MD, PhD 6; Paczesny, Sophie MD, PhD 7; Marsh, Steven G.E. PhD 8; Lee, Stephanie J. MD, MPH 5,9,; Spellman, Stephen R. MBS 3; Bolon, Yung-Tsi PhD 3; Fleischhauer, Katharina MD 1,2,,
doi : 10.1200/JCO.22.01229
Immunopeptidome divergence between mismatched HLA-DP is a determinant of T-cell alloreactivity and clinical tolerability after fully HLA-A, -B, -C, -DRB1, -DQB1 matched unrelated donor hematopoietic cell transplantation (UD-HCT).
Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.
Tilki, Derya MD 1,2,3,; Chen, Ming-Hui PhD 4,; Wu, Jing PhD 5; Huland, Hartwig MD 1; Graefen, Markus MD 1,; Mohamad, Osama MD, PhD 6,; Cowan, Janet E. MA 7,; Feng, Felix Y. MD 6,; Carroll, Peter R. MD, MPH 7,; D'Amico, Anthony V. MD, PhD 8,
doi : 10.1200/JCO.22.02489
Both the performance characteristics of prostate-specific membrane antigen positron emission tomography and insurance approval improves with increasing prostate-specific antigen (PSA) level causing some physicians to delay post-radical prostatectomy salvage radiation therapy (sRT) after PSA failure.
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis, Ursula A. MD 1,,; Lorusso, Domenica MD, PhD 2,; Oaknin, Ana MD, PhD 3,; Pignata, Sandro MD, PhD 4,; Dean, Andrew MBChB, MRCP, FRACP 5,; Denys, Hannelore MD, PhD 6,; Colombo, Nicoletta MD, PhD 7,8,; Van Gorp, Toon MD, PhD 9,; Konner, Jason A. MD 10,; Marin, Margarita Romeo MD, PhD 11,; Harter, Philipp MD, PhD 12,; Murphy, Conleth G. MD 13,; Wang, Jiuzhou PhD 14,; Noble, Elizabeth BS 14,; Esteves, Brooke BSN 14,; Method, Michael MD, MPH, MBA 14,; Coleman, Robert L. MD 15,
doi : 10.1200/JCO.22.01900
Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor [alpha] (FR[alpha]). SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC
Regarding Sequencing of Androgen-Deprivation Therapy.
Abner, Anthony MD; Vicini, Frank MD
doi : 10.1200/JCO.22.02824
Reply to A. Abner et al.
Martin, Ting MA; Sun, Yilun PhD; Spratt, Daniel E. MD; Kishan, Amar U. MD
doi : 10.1200/JCO.22.02824
More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?.
Tong, Wing H. MD, PhD, MSc; Mertens, Bart J. PhD
doi : 10.1200/JCO.22.02839
Reply to W.H. Tong et al.
Laetsch, Theodore W. MD; Tiwari, Ranjan MSc; Grupp, Stephan A. MD, PhD
doi : 10.1200/JCO.23.00187
Erratum: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
doi : 10.1200/JCO.23.00441
Erratum: Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
doi : 10.1200/JCO.23.00439
